Study on Clinical Features、Treatment and Prognosis of T-cell Non-Hodgkin’s Lymphomas
|School||Xinjiang Medical University|
|Keywords||T-cell non-Hodgkin’s lymphomas treatment over all survival prognosis|
Objective: This study was to analyze clinical features、treatment and prognosis of T-cell non-Hodgkin’s lymphomas.Methods: Records of 36 patients with T-cell lymphomas treated from Jan.2002 to Nov.2009 in our hospital.All patients were classifled according to REAL or WHO criteria and to analyze clinical features、treatment and prognosis of all the patients.Results: 6 cases were PTCL-U,6 were ALCL,6 were AITL,11 were NK/T,5 were TLBL, ATLL and SPTCL were both one case.Median age of the whole group was 43 years(ranged 11-75years);of 36 patients,14 were female,22 were male;28 were Han nationality,8 were minority ethnic group;27 patients were in the stage ofⅢ/Ⅳ; 22 patient were treated with chemotherapy alone.12 patients were treated with chemoradiotherapy and 1 patient was treated with radiotherapy only. After operation 1 patient died of septic shock. After the first line treatment,the complete remission(CR) rate and partial remission(PR) rate were 36.1%(13/36) and 36.1%(13/36) respectively.Median age of the whole group was 13.5(ranged0-112)years old.The 5-year survival rate was 41%.4 patients treated with autologous hematopoiesis stem cell transplantation after achieveing CR or PR. Kaplan-Meier analysis discovered that advanced stage(stageⅢ/Ⅳ)、LDH elevated、marrow involvement、B symptom were bad to prognosis,but Cox resression found that marrow involvement and LDH elevated were the independent bad factor to prognosis. The 5-year survival rate of low risk,low intermediate risk,intermediate high risk and high risk group were 78%、56%、15%、0%(P=0.004)。Conculsion:A rare lymphoma with aggressive presentation,T-NHL responds poorly to conventionat treatment. The prognosis of the cases with high risk is bad. APBSCT maybe improve the prognosis when CR or PR is achieved after first line treatment. .New treatment modality and prognosis factors for these patients need to be explored.